X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs AJANTA PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA AJANTA PHARMA SANOFI INDIA/
AJANTA PHARMA
 
P/E (TTM) x 40.1 20.3 197.6% View Chart
P/BV x 8.6 4.8 181.5% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 SANOFI INDIA   AJANTA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
AJANTA PHARMA
Mar-18
SANOFI INDIA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,818 250.8%   
Low Rs4,4001,106 397.8%   
Sales per share (Unadj.) Rs1,028.5239.5 429.5%  
Earnings per share (Unadj.) Rs129.052.8 244.3%  
Cash flow per share (Unadj.) Rs186.059.5 312.5%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.6230.0 327.7%  
Shares outstanding (eoy) m23.0388.77 25.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.46.1 71.3%   
Avg P/E ratio x34.727.7 125.4%  
P/CF ratio (eoy) x24.124.6 98.0%  
Price / Book Value ratio x5.96.4 93.5%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,174129,782 79.5%   
No. of employees `0003.66.8 53.3%   
Total wages/salary Rs m3,5923,765 95.4%   
Avg. sales/employee Rs Th6,537.73,128.4 209.0%   
Avg. wages/employee Rs Th991.4554.0 178.9%   
Avg. net profit/employee Rs Th819.8689.7 118.9%   
INCOME DATA
Net Sales Rs m23,68621,258 111.4%  
Other income Rs m708242 293.0%   
Total revenues Rs m24,39421,499 113.5%   
Gross profit Rs m5,2816,584 80.2%  
Depreciation Rs m1,313596 220.3%   
Interest Rs m154 365.9%   
Profit before tax Rs m4,6616,226 74.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,539 109.9%   
Profit after tax Rs m2,9704,686 63.4%  
Gross profit margin %22.331.0 72.0%  
Effective tax rate %36.324.7 146.7%   
Net profit margin %12.522.0 56.9%  
BALANCE SHEET DATA
Current assets Rs m15,67312,236 128.1%   
Current liabilities Rs m6,6783,461 193.0%   
Net working cap to sales %38.041.3 92.0%  
Current ratio x2.33.5 66.4%  
Inventory Days Days7660 126.2%  
Debtors Days Days2284 26.4%  
Net fixed assets Rs m8,09811,140 72.7%   
Share capital Rs m230177 130.2%   
"Free" reserves Rs m17,08820,237 84.4%   
Net worth Rs m17,35620,414 85.0%   
Long term debt Rs m010 0.0%   
Total assets Rs m25,40024,486 103.7%  
Interest coverage x311.71,519.4 20.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.9 107.4%   
Return on assets %11.819.2 61.3%  
Return on equity %17.123.0 74.5%  
Return on capital %26.930.5 88.3%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14511,667 61.2%   
Fx outflow Rs m6,8461,616 423.8%   
Net fx Rs m29910,052 3.0%   
CASH FLOW
From Operations Rs m3,2262,854 113.0%  
From Investments Rs m-1,555-2,604 59.7%  
From Financial Activity Rs m-1,818-2 90,900.0%  
Net Cashflow Rs m-147248 -59.3%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 1.6 929.0%  
FIIs % 14.6 7.6 192.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.0 61.8%  
Shareholders   15,184 20,968 72.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 25, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS